P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer

Hyuncheol Chung, SunYoung Rha, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyung Sik Lee, Byung Soo Kim, Kyi Beom Lee

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Expression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalBreast Cancer Research and Treatment
Volume42
Issue number1
DOIs
Publication statusPublished - 1997 Feb 11

Fingerprint

Induction Chemotherapy
P-Glycoprotein
Glycoproteins
Breast Neoplasms
Pharmaceutical Preparations
Inflammatory Breast Neoplasms
Recurrence
Adjuvant Chemotherapy
Fluorouracil
Doxorubicin
Cyclophosphamide
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chung, Hyuncheol ; Rha, SunYoung ; Kim, Joo Hang ; Roh, Jae Kyung ; Min, Jin Sik ; Lee, Kyung Sik ; Kim, Byung Soo ; Lee, Kyi Beom. / P-glycoprotein : The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. In: Breast Cancer Research and Treatment. 1997 ; Vol. 42, No. 1. pp. 65-72.
@article{a9bf540f9648472e931bb043e2d083cd,
title = "P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer",
abstract = "Expression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26{\%} and increased up to 58{\%} (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen.",
author = "Hyuncheol Chung and SunYoung Rha and Kim, {Joo Hang} and Roh, {Jae Kyung} and Min, {Jin Sik} and Lee, {Kyung Sik} and Kim, {Byung Soo} and Lee, {Kyi Beom}",
year = "1997",
month = "2",
day = "11",
doi = "10.1023/A:1005739525196",
language = "English",
volume = "42",
pages = "65--72",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

P-glycoprotein : The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. / Chung, Hyuncheol; Rha, SunYoung; Kim, Joo Hang; Roh, Jae Kyung; Min, Jin Sik; Lee, Kyung Sik; Kim, Byung Soo; Lee, Kyi Beom.

In: Breast Cancer Research and Treatment, Vol. 42, No. 1, 11.02.1997, p. 65-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - P-glycoprotein

T2 - The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer

AU - Chung, Hyuncheol

AU - Rha, SunYoung

AU - Kim, Joo Hang

AU - Roh, Jae Kyung

AU - Min, Jin Sik

AU - Lee, Kyung Sik

AU - Kim, Byung Soo

AU - Lee, Kyi Beom

PY - 1997/2/11

Y1 - 1997/2/11

N2 - Expression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen.

AB - Expression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen.

UR - http://www.scopus.com/inward/record.url?scp=0031018861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031018861&partnerID=8YFLogxK

U2 - 10.1023/A:1005739525196

DO - 10.1023/A:1005739525196

M3 - Article

C2 - 9116319

AN - SCOPUS:0031018861

VL - 42

SP - 65

EP - 72

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -